Histogenics Exec Kelley Moves To X4 Pharma as Chief Medical Officer

Lynne Kelley has joined X4 Pharmaceuticals (NASDAQ: [[ticker:XFOR]]) as chief medical officer, the same post she held at her former company, Histogenics (NASDAQ: [[ticker:HSGX]]). Kelley’s experience also includes positions at Senseonics (NASDAQ: [[ticker:SENS]]), Becton Dickinson (NYSE: [[ticker:BDX]]), Kimberly-Clark (NYSE: [[ticker:KMB]]), and Boston Scientific (NYSE: [[ticker:BSX]]). Cambridge, MA-based X4’s lead drug, Mavorixafor, is being prepared for Phase 3 studies in WHIM syndrome, a rare, inherited immunodeficiency.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.